‘Our major turning point came with the Zika virus outbreak’

EY Entrepreneur of the Year finalist Philip Noone of Aalto Bio

Philip Noone, Aalto Bio: ‘While the initial concern surrounding the Zika virus has subsided, there are still outbreaks together with ongoing Dengue and Chikungunya epidemics that mean a continual demand for these raw materials.’

Philip Noone, Aalto Bio: ‘While the initial concern surrounding the Zika virus has subsided, there are still outbreaks together with ongoing Dengue and Chikungunya epidemics that mean a continual demand for these raw materials.’

In the five years since he acquired Aalto Bio, Philip Noone has had remarkable success, gaining a foothold as the market leader in the diagnosis of the Zika virus, to name but one.

The company, founded in 1978 and based in Dublin, was taken over by Noone in 2014 following more than 20 years’ experience in the international medical diagnostics industry in companies including Diasorin, Quest and Trinity Biotech.

Please subscribe or sign in to continue reading.
only €1 first month

Insightful opinion is just a away.